Ratings Consun Pharmaceutical Group Limited Deutsche Boerse AG

Equities

C1P

KYG2524A1031

Market Closed - Deutsche Boerse AG Other stock markets 11:45:49 14/06/2024 am IST			5-day change	1st Jan Change
0.545 ^EUR	-19.85%		-39.11%	+2.83%

31/05	Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
24/05	Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Its low valuation, with P/E ratio at 5.16 and 4.44 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company shows low valuation levels, with an enterprise value at 0.69 times its sales.
The company appears to be poorly valued given its net asset value.
The company is one of the best yield companies with high dividend expectations.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CONSUN PHARMACEUTICAL GROUP LIMITED	+2.83%	603M		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B		B-
OTSUKA HOLDINGS CO., LTD.	+19.44%	21.78B		B+
SANDOZ GROUP AG	+17.85%	15.38B		-
CIPLA LIMITED	+25.55%	15.12B		B+
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B		B
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
ONO PHARMACEUTICAL CO., LTD.	-15.02%	6.38B		B+
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes